RareResearch.AI
← Back to atlas

c.1619_1642dup

In-frame indelI3Uncertain significanceTransmembrane · predicted
In-frame indel variant · indel site at position 540 · Transmembrane helix 8 · WFS1 (Wolframin)

I3 — Multi-residue in-frame indel — likely major structural disruption

Wild-type vs Modified Structure

Wild-type · full length
Wild-type wolframin · 890 aa — AlphaFold reference
Fullscreen ↗
Modified product
Modified product · c.1619_1642dup — Cα-RMSD 2.8 Å vs WT (folded core)
Fullscreen ↗

Left: full-length wild-type wolframin (890 aa). Right: the ColabFold (AlphaFold2) prediction of the 8-aa in-frame duplication product — the affected region near residue 540 (Transmembrane helix 8) is highlighted in both panes. Backbone Cα-RMSD over the folded core is 2.8 Å.

Variant Assessment

Variant type
In-frame indel
Schema
I3
Multi-residue in-frame indel — likely major structural disruption
Domain
Transmembrane helix 8
Backbone Cα-RMSD
2.8 Å
vs WT · folded core (n=351)

Modified-sequence structure resolved. The 8-aa in-frame duplication was modeled with ColabFold (AlphaFold2, full-MSA; mean pLDDT 69.4) and superposed on the wild-type AlphaFold model. Kabsch-superposed Cα-RMSD over high-confidence (WT pLDDT>70) residues N-terminal to the lesion; cross-pipeline, includes ~few-Å method baseline

Therapeutic Implication · I3

8 residues removed in frame around position 540 (Transmembrane helix 8). A change this size usually perturbs local packing and can propagate to the fold. Gene therapy is the primary path unless an AlphaFold prediction of the modified sequence shows a surprisingly intact fold. Predicted structure pending (ColabFold).

Clinical Evidence

ClinVar classificationUncertain significance
Review statuscriteria provided, single submitter
Associated conditionsWolfram syndrome 1
Population frequency (gnomAD v4)Absent from gnomAD v4
cDNA changec.1619_1642dup
ClinVar variantNM_006005.3(WFS1):c.1619_1642dup (p.Ile547_Leu548insArgCysGluLeuSerValValIle)
ClinVar accessionVCV004293404
Last evaluated2024/10/17 00:00

Not observed in ~730k individuals — consistent with a rare allele (ACMG PM2_supporting).

Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the c.1619_1642dup card below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals matched to this I3 in-frame indel variant and its domain context.

Download c.1619_1642dup PDF card ↓or markdown ↓

Full Variant Card

c.1619_1642dup — WFS1 Molecular Atlas Card

Variant type: In-frame indel Change: 8 residue(s) deleted in frame at position 540 Domain context: Transmembrane helix 8

Schema category: I3 — Multi-residue in-frame indel — likely major structural disruption

8 residues removed in frame around position 540 (Transmembrane helix 8). A change this size usually perturbs local packing and can propagate to the fold. Gene therapy is the primary path unless an AlphaFold prediction of the modified sequence shows a surprisingly intact fold. Predicted structure pending (ColabFold).

Structural prediction

  • Reading frame: preserved (in-frame) — no premature stop, NMD does not apply.
  • Affected domain: Transmembrane helix 8
  • Predicted modified structure: pending — AlphaFold/ColabFold prediction of the modified sequence and backbone-RMSD vs wild-type backfill here (Wave 2).

Clinical evidence

  • Classification: Uncertain significance
  • Review status: criteria provided, single submitter
  • Associated conditions: Wolfram syndrome 1
  • cDNA change: c.1619_1642dup
  • ClinVar accession: VCV004293404
  • Last evaluated: 2024/10/17 00:00
  • Submissions: 1

Card generated by wolfram-atlas-batch (in-frame indel pipeline) on 2026-06-08T02:41:27.373077Z. Schema: reference/card_schema_extension.md (I1–I3). WFS1: UniProt O76024, AlphaFold v6.